Prosynx develops invasive BCI hardware, including the 1,024-channel Tianshu implant system. The company has positioned the Tianshu system as moving beyond laboratory benchmarks toward human clinical testing. Prosynx announced plans to pursue clinical trials in 2026 for its implant. The recent RMB 330M (US$45.8M) angel raise is intended to accelerate that clinical push. The round was described as a record-sized angel financing in China's BCI sector and was backed by eight investors.

Total raised

$49M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2026